Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BHC INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Bausch Health Companies Inc.

T.BHC

NEW YORK, July 27, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Bausch Health Companies Inc. ("Bausch Health") (NYSE: BHC) concerning possible violations of federal securities laws.

Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP)

The investigation focuses on whether Bausch Health issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning its 2022 earnings and guidance and its patent dispute over Xifaxan. On May 10, 2022, Bausch Health announced its first-quarter 2022 results, prompting the stock price to fall $3.50 per share. Analysts attributed the decline to concerns around the Company's spin-off of Bausch + Lomb Corporation, high debt levels, and anticipation over the Xifaxan patent decision. On July 28, 2022, the Company issued an update on the Xifaxan patent dispute case between Bausch Health and Norwich. In response to this news, market analysts downgraded Bausch Health and its stock price fell an additional $3.58 per share, representing a decline of more than 50% from its trading price just two months earlier. . To obtain additional information, go to:

https://zlk.com/pslra-1/bausch-health-lawsuit-submission-form?prid=42625&wire=4

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bhc-investor-alert-levi--korsinsky-llp-notifies-investors-of-an-investigation-involving-possible-securities-fraud-violations-by-officers-of--bausch-health-companies-inc-301886822.html

SOURCE Levi & Korsinsky, LLP

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today